פוסטר 1006 ישראל - עברית - Ministry of Health

פוסטר 1006

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - תמיסה לשאיפה - formoterol fumarate dihydrate 6 mcg/dose; beclometasone dipropionate anhydrous 100 mcg/dose - formoterol and beclometasone - beclometasone - foster is indicated in the regular treatment of asthma where use of a combination product (inhaled corticosteroid and long-acting beta2-agonist) is appropriate:- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting beta2-agonist or- patients already adequately controlled on both inhaled corticosteroids and long-acting beta2-agonists.

דואו-רספ  ספירומקס  160 מקג 4.5 מקג ישראל - עברית - Ministry of Health

דואו-רספ ספירומקס 160 מקג 4.5 מקג

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 4.5 mcg/dose; budesonide micronized 160 mcg/dose - formoterol and budesonide

דואו-רספ  ספירומקס  320 מקג 9 מקג ישראל - עברית - Ministry of Health

דואו-רספ ספירומקס 320 מקג 9 מקג

abic marketing ltd, israel - budesonide micronized; formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 9 mcg/dose; budesonide micronized 320 mcg/dose - formoterol and budesonide

פוסטר 2006 ישראל - עברית - Ministry of Health

פוסטר 2006

kamada ltd, israel - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - formoterol fumarate dihydrate 6 mcg/actuation; beclometasone dipropionate anhydrous 200 mcg/actuation - formoterol and beclometasone

טרימבו ישראל - עברית - Ministry of Health

טרימבו

kamada ltd, israel - beclometasone dipropionate; formoterol fumarate dihydrate; glycopyrronium as bromide - glycopyrronium as bromide 9 mcg/delivered dose; formoterol fumarate dihydrate 5.2 mcg/delivered dose; beclometasone dipropionate 87.4 mcg/delivered dose - formoterol, glycopyrronium bromide and beclometasone

פורדיל כמוסות לשאיפה ישראל - עברית - Ministry of Health

פורדיל כמוסות לשאיפה

novartis israel ltd - formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 12 mcg - formoterol - formoterol - foradil is indicated in asthma ( including nocturnal asthma and exercise-induced symptoms) in those treated with inhaled corticosteroids who also require a long-acting beta agonist in accordance with current treatment guidelines.prophylaxis and treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (copd) including chronic bronchitis and emphysema.

טריקסאו אירוספייר ישראל - עברית - Ministry of Health

טריקסאו אירוספייר

astrazeneca (israel) ltd - budesonide; formoterol fumarate dihydrate; glycopyrronium - תרחיף לשאיפה - formoterol fumarate dihydrate 5 mcg; glycopyrronium 7.2 mcg; budesonide 160 mcg - budesonide

דואקליר ג'נואייר 34012 מקג ישראל - עברית - Ministry of Health

דואקליר ג'נואייר 34012 מקג

astrazeneca (israel) ltd - aclidinium as bromide; formoterol fumarate dihydrate - אבקה לשאיפה - formoterol fumarate dihydrate 11.8 mcg; aclidinium as bromide 340 mcg - aclidinium bromide

פלוטיפורם 505 ישראל - עברית - Ministry of Health

פלוטיפורם 505

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

פלוטיפורם 1255 ישראל - עברית - Ministry of Health

פלוטיפורם 1255

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.